Semaglutide 2.4 mg (Wegovy) is FDA-approved for noncirrhotic MASH with F2–F3 fibrosis, under accelerated approval granted in August 2025. In the ESSENCE trial it improved MASH resolution and, to a lesser degree, fibrosis. The phrase "treats fatty liver" conceals three different endpoints: reducing liver fat, resolving MASH inflammation and improving fibrosis are not the same thing, and no GLP-1 drug cures fatty liver.
Three endpoints hiding inside one phrase
A drug can succeed at one of these endpoints while barely touching another, so the claim that something helps fatty liver is incomplete until it specifies which one moved.
- Reduction in liver fat (steatosis) — how much fat is stored inside liver cells. GLP-1 medications reliably reduce this, largely through weight loss and improved insulin sensitivity.
- MASH resolution — clearing the inflammation and cell injury of steatohepatitis without worsening fibrosis. A harder and more meaningful endpoint.
- Fibrosis improvement — reducing the scar stage. The hardest endpoint of the three, the slowest to move, and the one most closely tied to long-term outcomes.
The distinction holds across the whole of MASLD: fat, MASH and fibrosis are separate things, measured separately. → Fatty Liver / MASLD hub
What the semaglutide approval says
Semaglutide 2.4 mg (Wegovy) received FDA accelerated approval for noncirrhotic MASH with F2–F3 fibrosis in August 2025, making it the first GLP-1 drug approved for MASH alongside resmetirom.
- The indication is narrow: MASH with moderate-to-advanced fibrosis (F2–F3). It does not cover cirrhosis (F4), and it does not cover simple fatty liver without significant fibrosis.
- The approval is accelerated, granted on histologic surrogate endpoints, with confirmatory long-term outcome data still maturing.
- In ESSENCE — noncirrhotic MASH, F2–F3, 72-week histology, part 1 — semaglutide 2.4 mg met both primary endpoints: MASH resolution without worsening fibrosis in 62.9% versus 34.3% on placebo, and ≥1-stage fibrosis improvement without worsening MASH in 36.8% versus 22.4% on placebo, both p<0.001.
Two terms in that indication carry weight. F2–F3 describes the stage of liver scarring: the middle band, where fibrosis is established but has not reached the F4 stage, which is cirrhosis. A surrogate endpoint is a measurement that stands in for the outcome that matters — here, changes in liver biopsy appearance standing in for later liver failure or liver cancer. Accelerated approval accepts that substitution on the understanding that the outcome data will follow.
The effect on inflammation is therefore larger than the effect on scarring, though the fibrosis benefit was statistically significant as well as smaller in absolute terms. Semaglutide is an approved option for the F2–F3 group, not a cure and not a liver drug for everyone with fat in the liver. → MASH Medications
Why GLP-1 drugs help the liver at all
The liver benefit is mostly indirect and metabolic rather than hepatic.
- Weight loss removes the energy surplus and central adiposity that drive hepatic fat, and the dose-response relationship between the amount lost and the liver response still applies. → Fatty Liver & Weight Loss
- Improved insulin sensitivity and glucose control reduce the metabolic signals that push fat and inflammation into the liver.
- Direct anti-inflammatory and metabolic effects on liver tissue are hypothesised but difficult to separate from the weight and glucose effects.
Because so much of the benefit tracks weight and metabolic improvement, GLP-1 therapy for the liver amounts to treating the metabolic disease that produced the fatty liver, which is how MASLD is best approached generally. → MASLD & Diabetes
Tirzepatide: promising, but not approved for MASH
Tirzepatide (Zepbound/Mounjaro), a GLP-1/GIP dual agonist, was studied for MASH in the SYNERGY-NASH trial and improved MASH resolution. It is not FDA-approved for MASH. Semaglutide is currently the GLP-1 carrying a MASH indication, and resmetirom is the other approved MASH drug, working through a different mechanism.
Tirzepatide produces greater average weight loss than semaglutide in head-to-head obesity data (SURMOUNT-5), which makes its liver signal biologically plausible, but a weight-loss advantage is not a regulatory MASH approval. Where a patient with MASH is already taking tirzepatide, the liver may still benefit from the weight and metabolic improvement; that use is off-label for the liver, and the formal MASH evidence base and approval sit with semaglutide and resmetirom. Grade B 🟡 (tirzepatide/MASH signal) → MASH Medications · /treat/glp1
What GLP-1 drugs do not do for the liver
- They do not cure or reverse fatty liver. They treat metabolic disease, and they do so dose-dependently.
- They are not approved for simple steatosis or for cirrhosis. The approval covers the F2–F3 MASH window only.
- They do not replace fibrosis assessment. Staging — FIB-4, then elastography — is what establishes whether a patient falls inside the group the approval targets. → FIB-4 · Elastography & Liver Fat
- Stopping the drug tends to bring weight back, and liver fat with it. Durability of the liver benefit after discontinuation is not established. → Fatty Liver & Weight Loss
What the evidence says: semaglutide for MASH
- What we know: in noncirrhotic MASH with F2–F3 fibrosis, semaglutide 2.4 mg improved MASH resolution (62.9% versus 34.3% on placebo) and fibrosis (≥1-stage improvement, 36.8% versus 22.4%), both endpoints met at p<0.001 in the 72-week ESSENCE analysis, with FDA accelerated approval in August 2025.
- What we don't know: long-term hard-outcome data, meaning progression to cirrhosis and liver events, are still maturing, and durability after stopping is unclear. The fibrosis benefit is smaller in absolute terms than the inflammation benefit.
- What we think: in our practice this is a genuine, approved advance for the F2–F3 MASH group, added to sustained lifestyle change rather than substituted for it, and not a fatty-liver drug for everyone. Grade A 🟢 (MASH resolution) / B 🟡 (fibrosis)
Whether a particular person falls inside the approved group, and what belongs alongside the drug, is what an individual assessment at the practice establishes.
Questions patients ask
Does semaglutide treat fatty liver?
It is FDA-approved for MASH with F2–F3 fibrosis and improves MASH inflammation — 62.9% versus 34.3% resolution in ESSENCE — and, to a smaller but still statistically significant degree, fibrosis, at 36.8% versus 22.4%. It reduces liver fat without curing fatty liver. Grade A 🟢
Is Wegovy the same as the MASH-approved drug?
Yes. The MASH-approved GLP-1 is semaglutide 2.4 mg, marketed as Wegovy. Ozempic is the same molecule at diabetes dosing, but it is not the product carrying the MASH indication. Grade A 🟢
Does tirzepatide (Zepbound) help fatty liver?
It improved MASH resolution in the SYNERGY-NASH trial and produces substantial weight loss, but it is not FDA-approved for MASH, so any liver benefit would be off-label. Grade B 🟡 → /treat/glp1
Will a GLP-1 reverse liver scarring?
Fibrosis can improve modestly, but it moves more slowly and less predictably than liver fat or inflammation. Scar reversal is not guaranteed. Grade B 🟡 → Elastography
Is a fibrosis test needed before starting a GLP-1 for the liver?
Yes. The approval targets F2–F3 MASH, so fibrosis staging — FIB-4, then liver elastography — is what shows whether the indication applies. Grade A 🟢 → FIB-4
How does semaglutide for MASH differ from resmetirom?
The mechanisms differ: semaglutide is a metabolic and weight drug, while resmetirom is a liver-targeted thyroid-hormone-receptor-β agonist. Both are approved for F2–F3 MASH. Grade A 🟢 → MASH Medications
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: Oct 2026 · References: FDA labeling for semaglutide 2.4 mg (MASH, Aug 2025); ESSENCE program; SYNERGY-NASH (tirzepatide); AASLD Practice Guidance on MASLD (2023). Regulatory status re-verified on update. Educational only; not individualized advice.
